BRPI0914504B8 - uso de um peptídeo intestinal vasoativo (piv) ou um ou mais fragmentos funcionais do piv - Google Patents
uso de um peptídeo intestinal vasoativo (piv) ou um ou mais fragmentos funcionais do pivInfo
- Publication number
- BRPI0914504B8 BRPI0914504B8 BRPI0914504A BRPI0914504A BRPI0914504B8 BR PI0914504 B8 BRPI0914504 B8 BR PI0914504B8 BR PI0914504 A BRPI0914504 A BR PI0914504A BR PI0914504 A BRPI0914504 A BR PI0914504A BR PI0914504 B8 BRPI0914504 B8 BR PI0914504B8
- Authority
- BR
- Brazil
- Prior art keywords
- piv
- prophylactic
- therapeutic treatment
- individual
- renal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
método de tratamento profilático ou terapêutico da doença renal crônica em um indivíduo, método de tratamento profilático ou terapêutico da insuficiência renal em um indivíduo , método de tratamento profilático ou terapêutico da fibrose renal em um indivíduo, método para reduzir os níveis, inibir ou reduzir a produção dos mediadores profibróticos em um indivíduo em risco de desenvolver ou que têm a doença renal crônica, a insuficiência renal e/ou a fibrose renal estabelecidas, método para reduzir a formação de colágeno ou intensificar a degradação do colágeno nos rins de um indivíduo, peptídeo intestinal vasoativo (piv) ou um ou mais fragmentos funcionais do piv, composição para o tratamento profilático ou terapêutico da doença renal crônica, composição para o tratamento profilático ou terapêutico da insuficiência renal e composição para o tratamento profilático ou terapêutico da fibrose renal a invenção refere-se às composições que compreendem o peptídeo intestinal vasoativo (piv) ou os fragmentos deste, e à utilização de tais composições no tratamento da doença renal, em particular, da fibrose renal, e em outras condições associadas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2008905378 | 2008-10-17 | ||
AU2008905378A AU2008905378A0 (en) | 2008-10-17 | Compositions and methods for treatment of kidney disorders | |
PCT/AU2009/001367 WO2010042997A1 (en) | 2008-10-17 | 2009-10-16 | Compositions and methods for treatment of kidney disorders |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0914504A2 BRPI0914504A2 (pt) | 2016-01-12 |
BRPI0914504B1 BRPI0914504B1 (pt) | 2020-11-10 |
BRPI0914504B8 true BRPI0914504B8 (pt) | 2021-05-25 |
Family
ID=42106133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0914504A BRPI0914504B8 (pt) | 2008-10-17 | 2009-10-16 | uso de um peptídeo intestinal vasoativo (piv) ou um ou mais fragmentos funcionais do piv |
Country Status (19)
Country | Link |
---|---|
US (2) | US8569235B2 (pt) |
EP (1) | EP2349320B1 (pt) |
JP (1) | JP2012505835A (pt) |
KR (1) | KR101671406B1 (pt) |
CN (1) | CN102186496A (pt) |
AU (1) | AU2009304595B2 (pt) |
BR (1) | BRPI0914504B8 (pt) |
CA (1) | CA2740989C (pt) |
DK (1) | DK2349320T3 (pt) |
ES (1) | ES2603963T3 (pt) |
HK (1) | HK1160598A1 (pt) |
IL (2) | IL212353A0 (pt) |
MX (1) | MX336384B (pt) |
MY (1) | MY160560A (pt) |
NZ (2) | NZ603602A (pt) |
RU (1) | RU2519124C2 (pt) |
SG (1) | SG10201501316VA (pt) |
WO (1) | WO2010042997A1 (pt) |
ZA (1) | ZA201103572B (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ597677A (en) * | 2005-12-09 | 2013-05-31 | Vectus Biosystems Ltd | Vip fragments and methods of use |
WO2007073486A2 (en) | 2005-12-20 | 2007-06-28 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
EP2307038A4 (en) | 2008-06-27 | 2013-03-27 | Univ Duke | THERAPEUTIC AGENTS COMPRISING ELASTINE-LIKE PEPTIDES |
DK2349320T3 (en) * | 2008-10-17 | 2016-09-26 | Vectus Biosystems Ltd | Compositions and methods for the treatment of renal disorders |
US8729020B2 (en) * | 2009-04-02 | 2014-05-20 | Vectus Biosystems Pty Ltd | Methods for the treatment of aortic fibrosis with VIP fragments |
ES2606140T3 (es) * | 2010-10-01 | 2017-03-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Métodos para predecir la progresión y tratar una enfermedad renal crónica en un paciente |
CN104130663B (zh) * | 2014-06-27 | 2017-01-04 | 南安市永腾技术咨询有限公司 | 一种用于包装机的金属防腐漆及其制备方法 |
WO2016145478A1 (en) | 2015-03-18 | 2016-09-22 | Vectus Biosystems Limited | Compositions for the treatment of kidney and/or liver disease |
US10437755B2 (en) | 2015-11-16 | 2019-10-08 | International Business Machines Corporation | Techniques for handling interrupts in a processing unit using virtual processor thread groups |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003253645A1 (en) | 2002-06-12 | 2003-12-31 | The Board Of Trustees Of The University Of Illinois | Phospholipid micelles in liposomes as solubilizers for water-insoluble compounds |
WO2004048401A1 (ja) * | 2002-11-27 | 2004-06-10 | Itoham Foods Inc. | ペプチド及びこれを含む医薬組成物 |
JP4824682B2 (ja) * | 2004-06-11 | 2011-11-30 | ベクタス・バイオシステムズ・リミテッド | 循環器病の治療のための組成物および方法 |
JP2008507540A (ja) * | 2004-07-21 | 2008-03-13 | チューレン ユニバーシティ ヘルス サイエンス センター | Pacap化合物を用いる腎臓機能障害及び多発性骨髄腫の治療 |
NZ597677A (en) * | 2005-12-09 | 2013-05-31 | Vectus Biosystems Ltd | Vip fragments and methods of use |
DK2349320T3 (en) * | 2008-10-17 | 2016-09-26 | Vectus Biosystems Ltd | Compositions and methods for the treatment of renal disorders |
US8729020B2 (en) * | 2009-04-02 | 2014-05-20 | Vectus Biosystems Pty Ltd | Methods for the treatment of aortic fibrosis with VIP fragments |
-
2009
- 2009-10-16 DK DK09820116.3T patent/DK2349320T3/en active
- 2009-10-16 ES ES09820116.3T patent/ES2603963T3/es active Active
- 2009-10-16 RU RU2011114857/15A patent/RU2519124C2/ru active
- 2009-10-16 NZ NZ603602A patent/NZ603602A/xx unknown
- 2009-10-16 KR KR1020117011192A patent/KR101671406B1/ko active IP Right Grant
- 2009-10-16 CA CA2740989A patent/CA2740989C/en active Active
- 2009-10-16 US US13/124,139 patent/US8569235B2/en active Active
- 2009-10-16 AU AU2009304595A patent/AU2009304595B2/en active Active
- 2009-10-16 JP JP2011531304A patent/JP2012505835A/ja active Pending
- 2009-10-16 NZ NZ592612A patent/NZ592612A/xx unknown
- 2009-10-16 SG SG10201501316VA patent/SG10201501316VA/en unknown
- 2009-10-16 CN CN2009801410744A patent/CN102186496A/zh active Pending
- 2009-10-16 WO PCT/AU2009/001367 patent/WO2010042997A1/en active Application Filing
- 2009-10-16 MY MYPI2011001651A patent/MY160560A/en unknown
- 2009-10-16 EP EP09820116.3A patent/EP2349320B1/en active Active
- 2009-10-16 MX MX2011004031A patent/MX336384B/es unknown
- 2009-10-16 BR BRPI0914504A patent/BRPI0914504B8/pt active IP Right Grant
-
2011
- 2011-04-14 IL IL212353A patent/IL212353A0/en active IP Right Grant
- 2011-05-16 ZA ZA2011/03572A patent/ZA201103572B/en unknown
-
2012
- 2012-01-31 HK HK12100865.8A patent/HK1160598A1/zh unknown
-
2013
- 2013-09-24 US US14/034,706 patent/US9238054B2/en active Active
-
2014
- 2014-11-25 IL IL235888A patent/IL235888A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
AU2009304595A1 (en) | 2010-04-22 |
HK1160598A1 (zh) | 2012-08-10 |
DK2349320T3 (en) | 2016-09-26 |
US9238054B2 (en) | 2016-01-19 |
NZ603602A (en) | 2013-09-27 |
US8569235B2 (en) | 2013-10-29 |
KR101671406B1 (ko) | 2016-11-01 |
MX2011004031A (es) | 2011-06-27 |
CN102186496A (zh) | 2011-09-14 |
US20140080758A1 (en) | 2014-03-20 |
EP2349320B1 (en) | 2016-06-22 |
EP2349320A4 (en) | 2012-12-26 |
AU2009304595B2 (en) | 2015-02-05 |
ZA201103572B (en) | 2012-01-25 |
JP2012505835A (ja) | 2012-03-08 |
CA2740989C (en) | 2016-07-12 |
BRPI0914504A2 (pt) | 2016-01-12 |
RU2011114857A (ru) | 2012-11-27 |
IL212353A0 (en) | 2011-06-30 |
KR20110095266A (ko) | 2011-08-24 |
SG10201501316VA (en) | 2015-05-28 |
BRPI0914504B1 (pt) | 2020-11-10 |
US20110218149A1 (en) | 2011-09-08 |
ES2603963T3 (es) | 2017-03-02 |
RU2519124C2 (ru) | 2014-06-10 |
CA2740989A1 (en) | 2010-04-22 |
WO2010042997A1 (en) | 2010-04-22 |
IL235888A (en) | 2017-08-31 |
MX336384B (es) | 2016-01-18 |
MY160560A (en) | 2017-03-15 |
EP2349320A1 (en) | 2011-08-03 |
NZ592612A (en) | 2013-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0914504B8 (pt) | uso de um peptídeo intestinal vasoativo (piv) ou um ou mais fragmentos funcionais do piv | |
BR0310099A (pt) | método para tratar dislipidemia ou uma doença associada com a dislipidemia | |
BRPI0510142A (pt) | compostos, composições e métodos para estabilizar a transtiretina e inibir a duplicação defeituosa da transtiretina | |
PH12015502275B1 (en) | Therapuetic uses of empagliflozin | |
WO2008115469A3 (en) | Role of hedgehog signaling in atherosclerosis and cardiovascular disease | |
BR112016013148A2 (pt) | "composições de rnai de componente do complemento e métodos de utilização das mesmas | |
NO20084368L (no) | Stabile emulsjonsformuleringer | |
NO20085243L (no) | Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting | |
BRPI0509366A (pt) | método para remover potássio de um indivìduo animal, formulação farmacêutica, métodos para tratar uma doença e para determinar uma permeabilidade de casca a um ìon, composição farmacêutica, composição de núcleo-casca,e, método para sintetizar um polìmero de alfa-fluroacrilato | |
DK1984357T3 (da) | 2,4-pyrimidindiaminforbindelser til behandling eller forebyggelse af autoimmunsygdomme | |
ECSP17000643A (es) | Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol. | |
NO20091700L (no) | Florizinanaloger som inhibitorer av glukose-ko-transporter 2 | |
DK2719708T3 (da) | Materiale og fremgangsmåder til behandling eller forebyggelse af her-3-relaterede sygdomme | |
WO2008016643A3 (en) | Certain chemical entities, compositions, and methods | |
NO20081425L (no) | 8-substituerte benzoazepiner som Toll-lignende reseptormodulatorer | |
BRPI0719849A2 (pt) | Método de imunização contra os quatro sorotipos da dengue | |
MX2020010004A (es) | Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos. | |
WO2009038842A3 (en) | Methods and compositions to inhibit edema factor and adenylyl cyclase | |
BRPI0814899A2 (pt) | Composição, vacina, metodo para amenizar um ou mais sintomas associados à infecção com o virus da influenza em um individuo e método para reduzir a probabilidade de infecção com o virus da influeza em um individuo" | |
BRPI0620566B8 (pt) | composição, composição para o tratamento profilático ou terapêutico de fibrose miocardial ou uma condição associada, composição para o tratamento profilático ou terapêutico de hipertensão, uso de uma composição, uso de vip ou de um fragmento do mesmo e uso de um vip | |
ATE481094T1 (de) | Behandlung von diabetischer nephropathie | |
BR112014017141A2 (pt) | método de tratamento de diabetes usando-se apolipoproteína a-iv não glicosilada | |
EA200970127A1 (ru) | Модулятор рецепторов глюкокортикостероидов и способы его применения | |
BR112012010184A2 (pt) | compósito. | |
WO2008016666A3 (en) | Certain chemical entities, compositions, and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/10/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |